Sichenzia Ross Ference LLP Represents INmune Bio, Inc. in $21.74 Million Public Offering of Common Stock
Press Release – New York, NY – July 17, 2020 – Sichenzia Ross Ference LLP announced that it represented INmune Bio Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, in a public offering of 2,173,914 shares of the company’s common stock at a price of $10.00 per share. The gross proceeds to INMB were $21.74 million, before deducting underwriting discounts and other offering expenses, with net proceeds estimated to be $20 million. The offering was made pursuant to a shelf registration statement on Form S-3 (File No. 333-237368), that was filed with the Securities and Exchange Commission (the “SEC”) and became effective on April 2, 2020.
The Sichenzia Ross Ference LLP team was led by partners Marc J. Ross, Thomas A. Rose, and David B. Manno.